Clinical Trial Search

Primary: Percentage of Subjects Maintaining Protective Anti- HAV Antibody Levels — 26 Participants

Primary: Seroprotection at Month 1 — 95.9; 96.6 percentage of participants

Primary: Hepatitis A Antibodies Titre — 9.4; 9.0; 394.7; 810.6 IU/L

Primary: Anti-hepatitis A (HAV) Antibody Concentrations — 1122.2; 1377.8; 998.6; 1347.1 mIU/mL

Primary: Number of Subjects With Anti-hepatitis A Virus (HAV) Antibody Concentrations Above the Cut-off Value — 113; 100; 105; 92 subjects

Primary: Antibody Response to Hepatitis A - Participants With a Serological Response — 182; 158 Participants — p=<0.001

Primary: Anti-hepatitis A Virus (Anti-HAV) Antibody Concentration — 748.1; 378.6; 419.3; 342.2 mIU/mL

Primary: Anti-hepatitis A Virus (HAV) Antibody Concentrations in HAV and HAV+MMR+V Groups. — 1390.4; 1895.2 mIU/mL

Primary: Participants With 1 or More Serious Vaccine-Related Adverse Experiences — 0; 1 participants

Primary: Anti-hepatitis A Virus (Anti-HAV) Antibody Concentration — 593.6; 297.4; 363.2; 287.7 mIU/mL

Primary: Number of Participants With Solicited Local Reactogenicity Events — 11; 3; 17; 1 Participants

Primary: Number of Subjects With Anti-hepatitis A Virus (HAV) Seropositivity Status at Approximately 8 Years Following Last Administered Havrix Dose — 223; 293; 77; 7 Participants

Primary: Number of Subjects With Anti-hepatitis A (Anti-HAV) Antibody Concentrations Equal to or Above Cut-off Value — 25; 28; 23; 24 Participants

Primary: Percentage of Participants HAV/Dengue Virus (DENV)-Naive at Baseline Who Are Seroprotected Against HAV at Day 30 — 97.1; 9.1; 98.7 percentage of participants

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 5; 4; 5; 4 Participants

Primary: Number of Subjects Seropositive for Anti-hepatitis A Virus Antibodies (Anti-HAV) and Anti-hepatitis B Surface Antigen (Anti-HBs) Antibodies and With Anti-HBs Antibody…

Primary: Geometric Mean antiHAV and antiHBV Concentrations (GMCs), 28 Days After Primary and Booster Vaccination — 48; 30; 786; 884 Concentrations (mIU/mL)

Primary: Anti-hepatitis A Virus (Anti-HAV) Antibody Concentration — 692.3; 753.6; 544.4; 479.5 milli-international units per milliliter

Primary: Anti-hepatitis A Virus (Anti-HAV) Antibody Concentration — 369.1; 323.5; 293.7; 298.2 mIU/mL

Primary: Incidence of Adverse Events (AEs) — 4; 3; 4; 5 Participants

Primary: The Incidence of Participants With Treatment-Emergent Adverse Events (TEAEs) and ≥Grade 3 Study Vaccine-related Adverse Events Following Study Vaccination — 1; 1; 2; 1…

Primary: Percent of Participants of Definite Hepatitis E by Category and Immunological Markers (Anti HEV) During the Follow-up Period — 0.0; 6.9; 0.3; 0.1 Percent of Participants

Primary: Effect of HSV-2 Suppression on HCV Viral Load. — .18; .03 log(IU/mL)

Primary: Change in HCV RNA Viral Load — .24; .08 log(IU/mL) — p=0.05

Primary: Number of Participants With Chronic Hepatitis C Virus (HCV) Infection at 6 Months — 14; 14 Participants — p=0.317

Primary: Change From Baseline in Plasma Log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Day 11 (Cohort A): Full Analysis Set — 6.11; -0.45 log10 IU/mL

Primary: Number of Participants With Vaccine-related Clinical (Systemic and Injection-site), and Laboratory Adverse Events (AE) — 5; 1; 3; 1 Participants

Primary: Number of Seropositive Subjects for Anti-hepatitis A Virus (HAV) Antibodies Following the Second Dose of Havrix — 88; 84; 77 Participants

Primary: Seropositivity Rate (SPR) to Hepatitis A — 100; 100; 100; 100 Percentage of participants

Primary: Number of Participants Who Experienced Norovirus Gastroenteritis (NVG) — 34; 37 Participants